Carbamazepine

證據等級: L5

預測適應症: 10 個

Carbamazepine: From Epilepsy / Trigeminal Neuralgia to Trigeminal Nerve Neoplasm

One-Sentence Summary

Carbamazepine (CBZ) is a well-established antiepileptic and first-line treatment for trigeminal neuralgia, widely used internationally to suppress abnormal neuronal firing through voltage-gated sodium channel blockade; it is not currently registered on the Australian Register of Therapeutic Goods (ARTG). The TxGNN model predicts it may be effective for Trigeminal Nerve Neoplasm — specifically for managing neuropathic pain arising from tumour compression or infiltration of the trigeminal nerve — with 1 clinical trial and 20 publications identified in this direction. Evidence is predominantly observational and case-based, supporting an L3 evidence level, and the mechanistic rationale is coherent but confined to symptomatic pain management rather than antitumour activity.

Quick Overview

Item	Content
Original Indication	Epilepsy; Trigeminal neuralgia (internationally established; no current ARTG registration — original indication data not available for Australia)
Predicted New Indication	Trigeminal Nerve Neoplasm
TxGNN Prediction Score	99.9976%
Evidence Level	L3 — Observational studies and case series
Australia Market Status	Not registered (no ARTG entries)
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current dataset. However, based on the extensive published literature linked to this Evidence Pack, Carbamazepine is a classic voltage-gated sodium channel blocker. By stabilising the inactivated state of Nav1.7 and Nav1.8 channels in trigeminal ganglion neurons, CBZ reduces the capacity of these cells to sustain the high-frequency burst firing that underlies trigeminal neuralgia (TN) pain. This mechanism is well-accepted and forms the basis of CBZ’s international first-line status for TN.

The predicted indication — trigeminal nerve neoplasm — encompasses tumours that compress, displace, or directly infiltrate the trigeminal nerve and its branches (e.g., schwannomas, meningiomas, lymphomas, epidermoid cysts, and primary melanomas in Meckel’s cave). When a mass lesion mechanically distorts the trigeminal nerve root, it induces focal demyelination and ectopic discharges at the affected segment — the same pathophysiological cascade as idiopathic TN. Multiple case reports in this dataset (PMIDs 30741017, 15235745, 25433061, 33989821, 26768887) document CBZ being prescribed as the first-line analgesic in patients who were subsequently found to have underlying neoplastic lesions. In one notable case (PMID 3181365), intravenous carbamazepine directly inhibited spontaneous ectopic discharges from experimental neuromas in an animal model, providing direct preclinical support for this mechanistic link.

It is critical to emphasise that CBZ is a symptomatic agent in this context, not an antitumour therapy. Its predicted utility in trigeminal nerve neoplasm is to control severe neuropathic pain while definitive oncological management (surgery, radiotherapy, or systemic therapy) is planned and executed. Clinicians should also note that failure of CBZ to control TN-like pain in a patient with negative initial imaging is an important red flag warranting repeat or gadolinium-enhanced MRI to exclude secondary neoplastic causes — as illustrated by the melanoma case in this dataset.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT06853119	N/A	Not Yet Recruiting	120	Observational MRI study examining brain network dynamics and microstructural changes in trigeminal neuralgia patients; evaluates blood-brain barrier integrity and neural plasticity. No CBZ intervention. Provides neuroimaging background context only — not a treatment trial.

Currently, no interventional clinical trials specifically evaluating Carbamazepine for trigeminal nerve neoplasm have been registered in ClinicalTrials.gov or ICTRP.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36824641	2022	Review	Acta Clinica Croatica	Comprehensive treatment review for TN; confirms CBZ as first-line medical therapy and explicitly states TN can be caused by vascular compression or a tumour process — directly relevant to this prediction
17997704	2007	Review	Expert Review of Neurotherapeutics	Detailed review of TN pathophysiology; discusses focal demyelination, ectopic discharge, and MRI for neurovascular contact — key mechanistic underpinning for CBZ use in neoplasm-related TN
11286444	2001	Cohort	British Journal of Oral & Maxillofacial Surgery	UK oral surgeon survey on TN management and CBZ monitoring practices; highlights that screening for secondary (neoplastic) TN remains a management consideration
3181365	1988	Experimental	Experimental Neurology	IV carbamazepine directly inhibited spontaneous ectopic discharges from saphenous neuromas in rats — preclinical evidence supporting CBZ suppression of neuroma/neoplasm-related aberrant firing
30741017	2023	Case Report	British Journal of Neurosurgery	Primary malignant lymphoma of trigeminal nerve presenting as facial pain; CBZ prescribed initially but did not improve symptoms — illustrates that neoplastic TN may be refractory to CBZ, underscoring the need for MRI
9109911	1997	Case Report	Neurology	Post-irradiation neuromyotonia in bilateral facial and trigeminal nerve distribution; responded to carbamazepine — radiation-induced nerve injury provides an analogy to neoplasm-related nerve dysfunction
15235745	2004	Case Report	Arquivos de Neuro-Psiquiatria	Primary melanoma of Meckel’s cave presenting as TN; pain was not relieved by CBZ or microvascular decompression — CBZ failure should prompt urgent MRI for neoplastic aetiology
22647513	2012	Case Report	No Shinkei Geka	Combined glossopharyngeal and trigeminal neuralgia; CBZ documented as standard first-line medical therapy before surgical microvascular decompression
25433061	2014	Case Report	No Shinkei Geka	TN caused by cerebellopontine angle lipoma; CBZ used but inadequately controlled due to side effects — surgical resection ultimately required
33989821	2021	Case Report	World Neurosurgery	Petroclival meningioma causing TN (<5% of cases); confirms that neoplasm-related TN is managed with initial medical therapy (CBZ context) before surgical intervention

Australia Market Information

Carbamazepine is not currently registered on the Australian Register of Therapeutic Goods (ARTG). No ARTG entries exist for this medicine under any brand name, dosage form, or route of administration in the current dataset.

Clinicians wishing to prescribe Carbamazepine in Australia would need to access it through one of the following TGA pathways:

Special Access Scheme (SAS) Category B — for individual patients with a serious or life-threatening condition
Authorised Prescriber pathway — if prescribing for a class of patients with a specific condition

Note: This finding is based on the data held in the current Evidence Pack (data cutoff: 21 June 2026). Given that Carbamazepine (e.g., Tegretol) is a well-established medicine internationally, prescribers should verify current ARTG status directly via the TGA Public Summary Search before assuming non-availability.

Safety Considerations

As Carbamazepine has no current TGA registration and no Australian Product Information (PI) is available, clinicians should consult an approved international prescribing reference (e.g., FDA prescribing information, UK Summary of Product Characteristics, or EMA SmPC). Safety data was not retrieved in this Evidence Pack (Data Gap DG001).

Key safety considerations known from established international evidence:

Black box / serious warnings: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) — risk is substantially elevated in patients carrying the HLA-B*15:01 allele, which is prevalent in East Asian and some South-East Asian populations represented in Australia’s multicultural community. Genetic screening is strongly recommended prior to initiation.
Haematological: Aplastic anaemia; agranulocytosis — baseline and periodic full blood count (FBC with differential) required
Electrolyte: Hyponatraemia and SIADH — monitor serum sodium, particularly in elderly patients
Hepatic: Elevations in liver enzymes — baseline and periodic liver function testing required
Endocrine / bone: Long-term CBZ induces CYP enzymes, accelerating vitamin D and hormone metabolism; bone mineral density monitoring warranted in chronic use
Teratogenicity: Known Category D teratogen (neural tube defects, cardiac malformations) — requires specialist counselling, high-dose folic acid, and contraception discussion in women of childbearing age
Drug interactions: CBZ is a potent inducer of CYP3A4, CYP2C9, and P-glycoprotein — extensive drug-drug interaction potential with oncological agents, anticoagulants, antiretrovirals, and many other commonly prescribed medicines. Formal DDI review was not completed in this dataset.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction is mechanistically coherent — CBZ’s established ability to suppress trigeminal ectopic discharge maps directly to the pain pathophysiology of trigeminal nerve neoplasm. Multiple case series and reviews confirm that CBZ is routinely used as initial symptomatic analgesia in this setting pending oncological management, and preclinical data directly support suppression of neuroma-generated firing. However, the evidence is L3 (case reports and observational data), no dedicated RCT exists, the drug has no current ARTG registration, and its role is purely symptomatic rather than disease-modifying.

To proceed, the following is needed:

TGA access pathway clarification: Confirm SAS Category B or Authorised Prescriber eligibility for the specific patient and indication prior to prescribing
HLA-B*15:01 genetic screening: Particularly important for patients of East Asian, South-East Asian, or South Asian descent — screen before first dose to mitigate SJS/TEN risk
Safety data retrieval: Download and parse the current international PI (DG001) to complete formal safety and contraindication assessment
MOA documentation: Retrieve full DrugBank API data for Carbamazepine (DG002) to formalise the mechanistic rationale in the clinical dossier
Oncology and neurosurgery consultation: Ensure CBZ is prescribed as adjunctive pain management, not a substitute for tumour-directed therapy; coordinate with the treating oncology and neurosurgery teams
Baseline and monitoring plan: Establish FBC with differential, LFTs, renal function, serum sodium, and body weight at baseline; schedule monitoring at 2–4 weeks, then 3-monthly during stable treatment
Pain reassessment trigger: Pre-specify a clear clinical threshold — if CBZ fails to control pain adequately within 4–6 weeks, or if any new neurological symptoms emerge, urgent gadolinium-enhanced MRI should be performed to reassess tumour status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.